OSF HealthCare Cancer Institute Begins Phase 3 Research Study of Investigational DLL3-Targeted Antibody-Drug Conjugate for Relapsed Small Cell Lung Cancer

DLLEVATE (ClinicalTrials.gov Identifier: NCT07218146) is a Phase 3 clinical trial evaluating an investigational therapy—ZL-1310, a DLL3-targeted antibody-drug conjugate (ADC) designed for targeted tumor cell killing—in adults with relapsed small cell lung cancer. The trial is part of a multicenter research effort.

“OSF HealthCare is relentless in driving forward oncology innovation, especially against tough cancers such as relapsed small cell lung cancer, through strategic alliances with forward-looking biotech innovators to deliver next-generation clinical trials to those who need them,” said Dr. Jun Zhang, Vice President of Oncology Research at OSF HealthCare Cancer Institute. “By joining these investigations, we empower appropriate patients with quicker access to novel investigational options that may help close key treatment shortfalls in this serious and frequently aggressive cancer.”

The study includes evaluation of the investigational therapy as a single agent compared to investigator’s choice of therapy (topotecan, lurbinectedin, or amrubicin), with all treatment approaches being studied for research purposes in accordance with the approved study protocol. All clinical research conducted at OSF HealthCare undergoes rigorous review and ongoing oversight to help ensure patient safety and ethical conduct.

Patients interested in learning more about clinical research at OSF HealthCare are encouraged to speak with their care team, call (844) 673-4467 or email sfmc.clinicaltrials@osfhealthcare.org.